【Obu City, Aichi Prefecture】'Metalo-Balance Test' to Assess Cancer and Cognitive Risks with Just 6mL of Blood Sample Begins at Mitsuba Clinic on August 1, 2026 (Sat)

Renatech Inc. (Headquarters: Isehara City, Kanagawa Prefecture), a company that develops health indicators based on trace elements and applies them to real-world use, announces the launch of its proprietary screening test, the 'Metalo-Balance Test,' which evaluates the risk of cancer and MCI (Mild Cognitive Impairment), at Mitsuba Clinic (Obu City, Aichi Prefecture) starting Saturday, August 1, 2026.

With the addition of this clinic, the testing infrastructure for the 'Metalo-Balance Test' in Obu City and surrounding areas will be further strengthened, providing local residents with a more accessible and innovative option for health management.

The company will continue to expand partnerships with medical institutions nationwide, aiming to encourage more individuals to take interest in their health and reconsider daily health habits and lifestyle choices as part of pre-disease care.

What is the Metalo-Balance (MB) Test?

The Metalo-Balance Test is a risk screening (triage) test that objectively evaluates the risk of cancer and MCI (Mild Cognitive Impairment) at the time of blood draw by analyzing the concentration balance of 17 trace elements (metal elements) in the blood.

### Features of the Test

- Only one 6mL blood draw: Blood is safely collected under the proper management of medical institutions. The test takes approximately 15 minutes, minimizing physical burden and ensuring safety.

- Site-specific 'Cancer Risk Test': In a single blood draw, cancer risks are evaluated by site (6 sites for men, 9 sites for women) and scored on a four-tier scale from A to D. - [Men] Lung cancer, stomach cancer, liver cancer, pancreatic cancer, colorectal cancer, prostate cancer - [Women] Lung cancer, stomach cancer, liver cancer, pancreatic cancer, colorectal cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer

- Comprehensive 'Cognitive Risk Test (MCI Risk Assessment)': Evaluates all types of MCI, including Alzheimer's type, vascular type, and Lewy body type.

- Proven research track record and international recognition: Developed through joint research with Kanagawa Prefectural Cancer Center and Chiba Cancer Center, supported by a research grant from the METI Go-Tech program. Patented in 9 countries including Japan, with over 100,000 test-takers cumulatively (from April 2019 to March 2026).

Testing Procedure and Key Pre-Test Instructions

* Due to the need for document mailing procedures, advance registration is required approximately three weeks before the desired test date (by complete reservation system).

- Registration: Please register via the website or by phone. A complete set of test documents will be delivered to your home approximately one week before your scheduled appointment.

- Test Day (Blood Draw): As the service operates on a complete reservation basis, blood collection will proceed smoothly (takes about 15 minutes). Payment is via convenience store post-payment, so there is no need to settle at the clinic on the day.

- Result Notification: Your invoice (payment slip) will be mailed to your home approximately three weeks after blood draw, and your test results will be sent approximately five weeks later.

### Key Pre-Test Instructions

- Food and Alcohol: No food after 9 PM the previous day. No alcohol from the previous day onward. - Hydration: Please drink sufficient water to facilitate blood collection. - Medications and Supplements: Over-the-counter medications and supplements should not be taken from the previous day onward. Prescription medications should be taken as usual.

Test Fees (Private Pay)

This test is a private-pay service not covered by health insurance. Please choose from the following plans according to your needs.

- Cancer Risk Test: 19,800 JPY (tax included) - Cognitive Risk Test: 19,800 JPY (tax included) - Cancer and Cognitive Risk Test Set: 24,200 JPY (tax included)

* Payment will be made via 'convenience store post-payment' delivered to your home after blood draw.

Eligibility and Important Notes for the Metalo-Balance Test

### Age Eligibility

- Cancer Risk Test: Japanese nationals aged 20 to 80 - Cognitive Risk Test: Japanese nationals aged 50 to 80

* As this test was developed based on data from Japanese individuals within the above age ranges, individuals outside these age groups or non-Japanese nationals may take the test, but results will be considered 'reference values' only. Please understand this in advance.

### Individuals Who Cannot Take the Test

- Pregnant individuals or those within 6 months postpartum - Individuals currently undergoing cancer treatment or within 1 year after completion of cancer treatment - Individuals undergoing dialysis - Individuals with fractures, blood disorders, or immunodeficiency (excluding lipid abnormalities such as high triglycerides) - Individuals in poor physical condition (including lack of sleep, after an all-nighter, immediately after intense exercise, under severe stress, or experiencing symptoms such as cold, asthma, shingles, allergic rashes, or allergic rhinitis)

Overview of the Newly Partnered Medical Institution

- Test Start Date: August 1, 2026 (Saturday) - Test Schedule: 1st Saturday and 3rd Thursday of each month (excluding holidays and clinic closure days)

- Medical Institution Name: Mitsuba Clinic - Address: 6-475 Kyoei-cho, Obu City, Aichi 474-0074 📍MAP - Access: 10-minute walk from JR Kyodo Station East Exit 🅿️ Parking available - Available Tests: Cancer Risk Test, Cognitive Risk Test

⚠️ Important Request Regarding Testing (Please Read Carefully)

- Please refrain from contacting the medical institution directly: The clinic's front desk or phone line cannot handle inquiries or registrations for this test. Please contact Renatech for any questions or registration.

- For details and registration, please visit:

- Metalo-Balance Test Information Site: https://www.mbkensa.com/

- Toll-Free Hotline: 0120-785-602 (Renatech: Weekdays 9:00–17:00)

▼ Digital Version of the Metalo-Balance Test Brochure

🏥 Partner medical institutions are being recruited nationwide! For information on introducing the Metalo-Balance Test, click here.

Metalona-chan, the official character of Metalo-Balance

Renatech Inc. is an innovation company developing proprietary technologies in the medical and health fields, as well as environmental fields, aiming to assess early risks of diseases such as cancer. The company has been selected as one of the '300 Outstanding SMEs and Small Businesses' by the Ministry of Economy, Trade and Industry (METI) and the Small and Medium Enterprise Agency, recognizing its high technological capabilities and social contributions.

Among its innovations, the 'Metalo-Balance Test' has gained significant attention as a groundbreaking screening technology that evaluates cancer and MCI (Mild Cognitive Impairment) risks by analyzing the concentrations of 17 trace elements in the blood. Moving forward, the company will continue to create new value for improving public health and solving societal challenges based on its advanced technological capabilities.

Company Overview

- Company Name: Renatech Inc. - Representative: Kei Kato, President & CEO - Headquarters: 4-19-15 Takamori, Isehara City, Kanagawa 259-1114 - URL: https://www.renatech.net/